NTLA
Intellia Therapeutics Inc

14,063
Mkt Cap
$1.09B
Volume
1.84M
52W High
$28.25
52W Low
$5.90
PE Ratio
-2.21
NTLA Fundamentals
Price
$9.44
Prev Close
$9.59
Open
$9.57
50D MA
$12.11
Beta
1.73
Avg. Volume
7.5M
EPS (Annual)
-$5.25
P/B
1.46
Rev/Employee
$143,615.39
Loading...
Loading...
News
all
press releases
Intellia Therapeutics (NASDAQ:NTLA) Cut to "Sell" at Wall Street Zen
Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Cathie Wood drops $8.9 million on energy stock
Whenever Cathie Wood trims her long-time favorite stock in Tesla (TSLA), it usually grabs headlines. However, what matters more is where that capital goes next. In ARK's Dec. 22 trades, Wood scaled...
TheStreet.com·5d ago
News Placeholder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus recommendation of "Hold" by the twenty-four ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·7d ago
News Placeholder
623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc
Marex Group plc bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·14d ago
News Placeholder
Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc.
Nikko Asset Management Americas Inc. trimmed its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.5% during the 2nd quarter, according to the company in its most...
MarketBeat·14d ago
News Placeholder
Intellia Therapeutics, Inc. $NTLA Shares Purchased by Armistice Capital LLC
Armistice Capital LLC raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 78.6% in the second quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·16d ago
News Placeholder
JPMorgan Chase & Co. Purchases 396,858 Shares of Intellia Therapeutics, Inc. $NTLA
JPMorgan Chase & Co. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 73.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·18d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Monday...
MarketBeat·20d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1% - Should You Buy?
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1% - What's Next...
MarketBeat·24d ago
News Placeholder
Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC
Orchard Capital Management LLC cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 57.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm...
MarketBeat·29d ago
<
1
2
...
>

Latest NTLA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.